GSK’s Jemperli meets main goal in mid-stage rectal cancer trial
July 13 (Reuters) - GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rate of patie...
Read the full articleYou might also wanna read
GSK Achieves Promising Results in Rectal Cancer Trial with Jemperli
Related Stocks: GSK
GuruFocus·3d ago
GSK to file Jemperli for rectal cancer after phase 3 readout
GSK to file Jemperli for rectal cancer after phase 3 readout Phil.Taylor Mon, 13/07/2026 - 11:42
pharmaphorum·3d ago
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
Results support potential for dostarlimab to eliminate the need for chemotherapy, radiation and surgery in some patients
GSK·3d ago
Lung cancer drug hits main goal in trial
Lung cancer drug hits main goal in trial
ARY NEWS·4d ago
Abivax's inflammatory bowel drug meets main goal of late stage trial
Abivax's inflammatory bowel drug meets main goal of late stage trial reut.rs/4dVJ1tx
reuters.com·1mo ago
GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer
GSK announced results of a Phase III study - pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo.1
GSK·17y ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.